Trial Profile
An Open Label Phase I Trial of Alemtuzumab (Campath 1-H) Therapy for Refractory Chronic Graft-vs-Host Disease.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2013
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 25 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Jun 2011 Planned End Date changed from 1 Jan 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 26 Jan 2010 Genzyme Corporation added as trial sponsor as reported by ClinicalTrials.gov.